Signal #150111 · SEC 8-K

$ALLO SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $ALLO filing catalyst

Why did $ALLO trigger an AI stock catalyst alert?

$ALLO triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: -0.5/10). Headline: Allogene Reports Q3 Net Loss of $50.4M, Cash Position at $388.9M. Key points: - Net loss widened to $50.4M ($0.15/share) from $41.4M ($0.19/share) in Q3 prior year, driven by higher R&D expenses. - Cash, cash equivalents and investments totaled $388.9M as of September 30, 2026. - Next pivotal Phase 2 ALPHA3 trial clinical update scheduled for mid-2027.

How did $ALLO stock react after the SEC filing?

After the SEC 8-K for $ALLO, observed market reaction: T0 price $1.09. Past moves do not guarantee future results.

Where can I get real-time $ALLO SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $ALLO via Telegram and the VIP Web Terminal from €10/month.

$ALLO

$ALLO – Allogene Reports Q3 Net Loss of $50.4M, Cash Position at $388.9M

Allogene Therapeutics, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $ALLO

Unlocked archive · Analyzed in <2s at T0

Neutral AI Sentiment (-0.5 / 10)

Net loss widened to $50.4M ($0.15/share) from $41.4M ($0.19/share) in Q3 prior year, driven by higher R&D expenses.
Cash, cash equivalents and investments totaled $388.9M as of September 30, 2026.
Next pivotal Phase 2 ALPHA3 trial clinical update scheduled for mid-2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →